|
|
|
30.06.25 - 17:30
|
Number of shares and votes in Orexo (Cision)
|
|
|
Uppsala, Sweden – June 30, 2025 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), announces that, during June 2025, the number of shares and votes in the company has changed as a result of the issue and repurchase of class C shares as announced on June 18, 2025. In total, the number of shares has increased by 2,446,000 class C shares and the votes have increased by 244,600.
Today, the last trading day of the month, there are in total 37,156,639 shares in Orexo - whereof 34,710,639 are ordinary shares with one vote per share and 2,446,000 are class C shares with one tenth of a vote per...
|
|
|
02.06.25 - 15:16
|
Orexo to present clinical data for OX640 at the EAACI Congress (PR Newswire)
|
|
|
OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of severe allergic reactions (including anaphylaxis) and is based on the proprietary AmorphOX® technology EAACI is a leading global association devoted to allergic and immunology diseases Orexo´s advisor Dr.......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
24.10.24 - 09:37
|
Orexo Interim Report Q3 2024 (PR Newswire)
|
|
|
UPPSALA, Sweden, Oct. 24, 2024 /PRNewswire/ -- Q3 2024 highlights › Total net revenues of SEK 136.5 m (156.1) › EBITDA of SEK -0.7 m (-9.5) › Net earnings of SEK -41.9 m (-33.3) › US Commercial segment net revenues of SEK 131.0 m (140.4), in local currency USD 12.6 m (13.0) › Cash flow......
|
|
|
24.10.24 - 09:32
|
Orexo Interim Report Q3 2024 (PR Newswire)
|
|
|
UPPSALA, Sweden, Oct. 24, 2024 /PRNewswire/ -- Q3 2024 highlights › Total net revenues of SEK 136.5 m (156.1) › EBITDA of SEK -0.7 m (-9.5) › Net earnings of SEK -41.9 m (-33.3) › US Commercial segment net revenues of SEK 131.0 m (140.4), in local currency USD 12.6 m (13.0) › Cash flow......
|
|
|
08.10.24 - 10:01
|
Orexo: Salem Tewolde, Head of Supply Chain, on solving real problems (Cision)
|
|
|
News Release
Salem shares her experiences of heading up the supply chain at Orexo, ensuring timely delivery of Zubsolv® and preparing to launch OX124. Furthermore, her passion for enabling sustainability.
Hi Salem, how would you describe your role as Head of Supply Chain?
I work with my team to make sure we have everything in place to maintain an uninterrupted supply of our commercial products to distribute. Right now, one of our primary focuses is on ensuring a sustainable supply chain for OX124, our high-dose rescue medication. A large part of my role is ensuring that the supply...
|
|
|
|
|
03.09.24 - 09:01
|
Orexo to participate in Pareto Securities’ 15th Annual Healthcare Conference 2024 (Cision)
|
|
|
Uppsala, Sweden – September 3, 2024 – Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY), today announces the company will participate in Pareto Securities´ 15th Annual Healthcare Conference, that takes place on September 19, at Downtown Camper by Scandic, Brunkebergstorg 9, Stockholm, Sweden.
On the day, between 2:25-2:45 CET (room Event Small), Robert Rönn, SVP and Head of R&D, will give a company presentation. Robert Rönn and Lena Wange, Investor Relations, will also be available for 1-1 meetings.
For more information, please contact:
Orexo AB (publ.)
Lena Wange, IR &...
|
|
|
|
|
17.07.24 - 08:33
|
Orexo Q2 2024 Interim Report (PR Newswire)
|
|
|
UPPSALA, Sweden, July 17, 2024 /PRNewswire/ -- Making progress, while the OX124 review time extended Q2 2024 highlights Total net revenues of SEK 154.0 m (157.7) EBITDA of SEK 5.0 m (5.6) Net earnings of SEK -35.9 m (-12.6) US Commercial segment net revenues of SEK 147.9 m (145.4), in......
|
|
|
17.07.24 - 08:31
|
Orexo Q2 2024 Interim Report (PR Newswire)
|
|
|
UPPSALA, Sweden, July 17, 2024 /PRNewswire/ -- Making progress, while the OX124 review time extended Q2 2024 highlights Total net revenues of SEK 154.0 m (157.7) EBITDA of SEK 5.0 m (5.6) Net earnings of SEK -35.9 m (-12.6) US Commercial segment net revenues of SEK 147.9 m (145.4), in......
|
|
|
17.07.24 - 08:01
|
Orexo Q2 2024 Interim Report (Cision)
|
|
|
Making progress, while the OX124 review time extended
Q2 2024 highlights
› Total net revenues of SEK 154.0 m (157.7)
› EBITDA of SEK 5.0 m (5.6)
› Net earnings of SEK -35.9 m (-12.6)
› US Commercial segment net revenues of SEK 147.9 m (145.4), in local currency USD 13.9 m (13.8)
› Cash flow from operating activities of SEK -6.5 m (-12.7), cash and cash equivalents of SEK 139.7 m (251.1)
› Earnings per share before and after dilution amounted to SEK -1.04 (-0.37)
› Second patent in the US granted for OX640, a nasal epinephrine powder product
› The...
|
|
|
|
|
16.07.24 - 20:03
|
Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose (Cision)
|
|
|
Uppsala, Sweden – July 16, 2024 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces that the company has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for OX124, a high-dose naloxone rescue medication in development for opioid overdose. The NDA was submitted to the FDA on September 18, 2023. The CRL indicates the need for an additional Human Factors (HF) study, which is in line with previous communication. Furthermore, additional technical data on the final commercial product has been requested. The...
|
|
|
10.07.24 - 08:36
|
Orexo AB’s sustainability work ranked among top 5% by EcoVadis (PR Newswire)
|
|
|
UPPSALA, Sweden, July 10, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) announces that it has received a Gold Sustainability Rating by EcoVadis, one of the world´s most trusted provider of business sustainability ratings. The highly revered award places the company in the......
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
